Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Positive Phase III results for PEG-intron

Enzon (ENZN) partner Schering-Plough (SGP) reported results of a 1,219-patient Phase III trial showing that PEG-Intron pegylated interferon alfa-2b, which uses ENZN's polyethylene glycol (PEG) technology,

Read the full 263 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE